← Back to Clinical Trials
Recruiting NCT07526012

NCT07526012 Comparative Effects Of Post Isometric Relaxation Versus Active Isolated Stretch In Patients With Piriformis Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07526012
Status Recruiting
Phase
Sponsor Foundation University Islamabad
Condition Piriformis Syndrome
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-05-20
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Post Isometric RelaxationActive Isolated Stretching

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-05-20 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the comparative effects of post-isometric relaxation (PIR) and active isolated stretch (AIS) techniques on reducing pain, improving range of motion, and decreasing functional disability in individuals with piriformis syndrome. A total of 40 participants will be recruited, aged 20-55 yrs, with confirmed piriformis syndrome. Participants will be randomized into two equal groups. Group A (post isometric relaxation) and Group B (active isolated stretch). Both groups will receive Conventional Therapy (Thermotherapy, Electrotherapy). Study variables include: * Independent Variable: Post Isometric Relaxation and Active Isolated Stretching. * Dependent Variables: Pain (measured by Visual Analog Scale), Functional Disability (assessed via Oswestry Disability Index), Range of Motion (assessed via Goniometer). * Control Variables: Age, Gender, BMI, Baseline Pain/ Disability Scores/ROM The intervention will last 2 weeks with 6 sessions (3 sessions per week). Assessments will be conducted at baseline (Week 1, Pre-treatment) and Post every second session. Data will be analyzed to compare immediate and short-term effects of the two interventions. This study aims to provide evidence for targeted manual therapy approaches in priformis syndrome, potentially guiding clinicians toward the most effective technique for pain reduction, improve ROM and decrease functional disability.

Eligibility Criteria

Inclusion Criteria: * Age between 20-55 years * Both genders * Buttock pain that may radiates to posterior thigh but not beyond the knee * Pain aggravated by sitting, climbing stairs or hip rotation. * Tenderness upon palpation over the sciatic foramen. * Positive FAIR test. Exclusion Criteria: * Malignancies * History of steroid therapy over 3 months * Rheumatoid arthritis or osteoarthritis * Avascular necrosis of the femoral head * Osteoporosis * Fracture of the femur * Hip deformity

Contact & Investigator

Central Contact

Parsa Saghir, DPT

✉ parsa.saghir@gmail.com

📞 0315-8962525

Principal Investigator

Parsa Saghir, DPT

PRINCIPAL INVESTIGATOR

Foundation University Islamabad

Frequently Asked Questions

Who can join the NCT07526012 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 55 Years, studying Piriformis Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07526012 currently recruiting?

Yes, NCT07526012 is actively recruiting participants. Contact the research team at parsa.saghir@gmail.com for enrollment information.

Where is the NCT07526012 trial being conducted?

This trial is being conducted at Islamabad, Pakistan.

Who is sponsoring the NCT07526012 clinical trial?

NCT07526012 is sponsored by Foundation University Islamabad. The principal investigator is Parsa Saghir, DPT at Foundation University Islamabad. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology